Posted by Michael Wonder on 25 Mar 2026
Triana Biomedicines’ TRI-611 granted US FDA fast track designation for treatment of ALK positive non-small cell lung cancer
25 March 2026 - Triana Biomedicines today announced that the US FDA granted fast track designation for TRI-611, an investigational molecular glue degrader therapy for the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer.
TRI-611 is a novel oral, small molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK positive NSCLC.
